Hjem › Kronisk lymfatisk leukæmi › Indiana
Kronisk lymfatisk leukæmi kliniske forsøg i Indiana
12 studier for Kronisk lymfatisk leukæmi søger deltagere på steder i Indiana.
Byer i Indiana
Officiel studietekst (engelsk)
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Reid Health, Richmond
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 101, Fort Wayne
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT07582432Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- UChicago Medicine Northwest Indiana, Crown Point
- Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT04269902A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT06697184A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Fort Wayne Medical Oncology and Hematology ( Site 5444), Fort Wayne
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Parkview Research Center at Parkview Regional Medical Center ( Site 0002), Fort Wayne
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06136559Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Indiana University Health Arnett, Inc., Lafayette
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 21. sep. 2026 · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Fort Wayne Oncology and Hematology, Fort Wayne
- Hematology Oncology of Indiana, Indianapolis
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Fort Wayne Medical Oncology and Hematology, Fort Wayne
- Hematology Oncology of Indiana, Indianapolis
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 31. aug. 2026 · NCT07516093A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Northwest Cancer Center - Dyer Clinic /ID# 268478, Dyer
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 9. apr. 2026 · NCT06428019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- American Oncology Partners, Fort Wayne
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. dec. 2025 · NCT05602363Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
- Goshen Center for Cancer Care, Goshen
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2022 · NCT04502394Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.